Losmapimod - CAS# 585543-15-3 Size:Solid 2 mg Smiles: CC(OC(=O)OC1CCCCC1)OC(=O)C1=CC=CC2N=C(OCC)N(CC3C=CC(=CC=3)C3=CC=CC=C3C3NN=NN=3)C=21

Smiles: CC(OC(=O)OC1CCCCC1)OC(=O)C1=CC=CC2N=C(OCC)N(CC3C=CC(=CC=3)C3=CC=CC=C3C3NN=NN=3)C=21

Norris-Drouin J

H2O/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27

11aS)-11a-methyl-1H

Oseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo

Losmapimod - CAS# 585543-15-3 Size:Solid 2 mg Smiles: CC(OC(=O)OC1CCCCC1)OC(=O)C1=CC=CC2N=C(OCC)N(CC3C=CC(=CC=3)C3=CC=CC=C3C3NN=NN=3)C=21Losmapimod, also know as GW856553 or GW856553X or GSK AHAB, is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen activated protein kinases. p38 mitogen activated protein kinases are mediators of inflammation. A Phase II human clinical trial for the treatment of COPD (chronic obstructive pulmonary disease) is underway. Inhibiting these enzymes has been shown to produce antidepressant and